References of "Jerusalem, Guy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailImpact de la double stigmatisation en oncogériatrie : Etat des lieux
Schroyen, Sarah ULg; Adam, Stéphane ULg; JERUSALEM, Guy ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(2), 131-8

Detailed reference viewed: 112 (36 ULg)
See detailClinical significance of MT4-MMP and EGFR expression in Breast Cancer
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2014, May 19)

Detailed reference viewed: 18 (3 ULg)
Full Text
See detailExtended adjuvant endocrine therapy. Who benefits ? For how long ?
JERUSALEM, Guy ULg

Conference (2014, April 24)

Detailed reference viewed: 12 (2 ULg)
Full Text
See detailNew chemotherapy drugs in metastatic breast cancer
JERUSALEM, Guy ULg

Conference (2014, February 22)

Detailed reference viewed: 14 (0 ULg)
See detailStudy of the pro-tumoral effects of MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2014, January 27)

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailLE DÉFI DU CONTRÔLE LOCAL DANS LE CANCER PULMONAIRE NON A PETITES CELLULES, LOCALEMENT AVANCE, NON OPERABLE
BARTHELEMY, Nicole ULg; LENNERTS, Evelyne ULg; MEYNS, Mia ULg et al

in Revue Médicale de Liège (2014), 69(Supp 1), 75-80

Le cancer broncho-pulmonaire non à petites cellules (CBNPC) est fréquent. Pour près d’un patient sur cinq, au moment du diagnostic, la maladie est déjà localement avancée et inopérable. A ce stade, le ... [more ▼]

Le cancer broncho-pulmonaire non à petites cellules (CBNPC) est fréquent. Pour près d’un patient sur cinq, au moment du diagnostic, la maladie est déjà localement avancée et inopérable. A ce stade, le pronostic de cette affection est mauvais, caractérisé, entre autres, par un taux élevé de réci - dive locale, malgré la chimiothérapie et la radiothérapie. Le but de cette revue est de décrire l’hétérogénéité de ce groupe de patients, de clarifier les modalités de traitement combinant la chimiothérapie et la radiothérapie et de préciser l’intérêt des techniques modernes de radiothérapie pour améliorer le contrôle local [less ▲]

Detailed reference viewed: 117 (14 ULg)
Full Text
Peer Reviewed
See detailLe traitement multidisciplinaire du glioblastome
BARTHELEMY, Nicole ULg; GENNIGENS, Christine ULg; Scholtes, Félix ULg et al

in Revue Médicale de Liège (2014), 69

Detailed reference viewed: 131 (50 ULg)
Full Text
Peer Reviewed
See detailExpert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Plana, Juan Carlos; Galderisi, Maurizio; Barac, Ana et al

in Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2014), 27(9), 911-39

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailVieillissement et cancer: coincidence ou relation etiologique?
Duray, A.; Demoulin, Stéphanie ULg; Petermans, Jean ULg et al

in Revue medicale de Liege (2014), 69(5-6), 276-81

In Belgium and in other countries, the Cancer Registry data show an increased incidence of cancers related to age, the majority of tumors being diagnosed beyond 60 years. However, the mechanisms ... [more ▼]

In Belgium and in other countries, the Cancer Registry data show an increased incidence of cancers related to age, the majority of tumors being diagnosed beyond 60 years. However, the mechanisms responsible for this increase are not clear. Cancer could be chronologically associated with aging because of the long latency period between the exposition to carcinogenic agents and the appearance of clinical signs. Aging could also predispose directly to cancer by different mechanisms (impaired immune response, increased oxidative stress, shortening of telomeres, accumulation of senescent cells). In this review, we propose to describe different hypotheses which could explain the increased incidence of cancers in the elderly. [less ▲]

Detailed reference viewed: 49 (0 ULg)
Full Text
Peer Reviewed
See detailExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Plana, Juan Carlos; Galderisi, Maurizio; Barac, Ana et al

in European heart journal cardiovascular Imaging (2014), 15(10), 1063-93

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailL'âgisme et ses conséquences cliniques en oncogériatrie: état des lieux et pistes d'interventions
Schroyen, Sarah ULg; Adam, Stéphane ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2014), 69(5-6), 395-401

Detailed reference viewed: 103 (27 ULg)
Full Text
Peer Reviewed
See detailPhase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura, Cristina; Bendell, Johanna; Jerusalem, Guy ULg et al

in Clinical cancer research : an official journal of the American Association for Cancer Research (2014), 20(7), 1935-45

PURPOSE: Phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation in patients with HER2-positive (HER2(+)) breast cancer has been implicated in de novo and acquired trastuzumab resistance. The purpose ... [more ▼]

PURPOSE: Phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation in patients with HER2-positive (HER2(+)) breast cancer has been implicated in de novo and acquired trastuzumab resistance. The purpose of this study was to determine the clinical activity of the PI3K inhibitor buparlisib (BKM120) in patients with HER2(+) advanced/metastatic breast cancer resistant to trastuzumab-based therapy. EXPERIMENTAL DESIGN: In the dose-escalation portion of this phase I/II study, patients with trastuzumab-resistant locally advanced or metastatic HER2(+) breast cancer were treated with daily oral doses of buparlisib and weekly intravenous trastuzumab (2 mg/kg). Dose escalation was guided by a Bayesian logistic regression model with overdose control. RESULTS: Of 18 enrolled patients, 17 received buparlisib. One dose-limiting toxicity of grade 3 general weakness was reported at the 100-mg/day dose level (the single-agent maximum tolerated dose) and this dose level was declared the recommended phase II dose (RP2D) of buparlisib in combination with trastuzumab. Common (>25%) adverse events included rash (39%), hyperglycemia (33%), and diarrhea (28%). The pharmacokinetic profile of buparlisib was not affected by its combination with trastuzumab. At the RP2D, there were two (17%) partial responses, 7 (58%) patients had stable disease (>/=6 weeks), and the disease control rate was 75%. Pharmacodynamic studies showed inhibition of the PI3K/AKT/mTOR and RAS/MEK/ERK pathways. CONCLUSIONS: In this patient population, the combination of buparlisib and trastuzumab was well tolerated, and preliminary signs of clinical activity were observed. The phase II portion of this study will further explore the safety and efficacy of this combination at the RP2D. Clin Cancer Res; 20(7); 1935-45. (c)2014 AACR. [less ▲]

Detailed reference viewed: 42 (4 ULg)